Targeting an energy sensor to prevent energy excess in the liver

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the era of the obesity pandemic.1,2 Fat accumulation in the liver results from an imbalance between lipid metabolism and intake, partly contributed to by excessive dietary consumption and hepatic de-novo lipogenesis. Currently, researchers and companies are racing to develop novel therapeutics with different mechanisms of action for non-alcoholic steatohepatitis (NASH), targeting lipid metabolism, inflammatory, or fibrotic pathways.